TY - JOUR
T1 - Dysregulated signaling pathways in the development of CNTRL-FGFR1–induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models
AU - Ren, Mingqiang
AU - Qin, Haiyan
AU - Kitamura, Eiko
AU - Cowell, John K.
N1 - Funding Information:
This work was supported in part by a grant from the National Institutes of Health (CA076167). J.K.C. is a Georgia Cancer Coalition Scholar.
Funding Information:
The authors thank Dr Toshimitsu Matsui (Kobe University, Kobe, Japan) for providing the sample from the CNTRL-FGFR1 patient and Drs Jun Qi and James E. Bradner (Dana-Farber Cancer Institute, Boston, MA) for kindly supplying the JQ1 drug. This work was supported in part by a grant from the National Institutes of Health (CA076167). J.K.C. is a Georgia Cancer Coalition Scholar.
Publisher Copyright:
© 2013 by The American Society of Hematology.
PY - 2013/8/8
Y1 - 2013/8/8
N2 - Myeloid and lymphoid neoplasm associated with FGFR1 is an aggressive disease, and resistant to all the current chemotherapies. To define the molecular etiology of this disease, we have developed murine models of this disease, in syngeneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rγnull mice engrafted with transformed human CD341 hematopoietic stem/progenitor cells. Both murine models mimic the human disease with splenohepatomegaly, hypercellular bone marrow, and myeloproliferative neoplasms that progresses to acute myeloid leukemia. Molecular genetic analyses of these model mice, as well as primary human disease, demonstrated that CNTRL-FGFR1, through abnormal activation of several signaling pathways related to development and differentiation of both myeloid and T-lymphoid cells, contribute to overt leukemogenesis. Clonal evolution analysis indicates that myeloid related neoplasms arise from common myeloid precursor cells that retain potential for T-lymphoid differentiation. These data indicate that simultaneously targeting these pathways is essential to successfully treating this almost invariably lethal disease.
AB - Myeloid and lymphoid neoplasm associated with FGFR1 is an aggressive disease, and resistant to all the current chemotherapies. To define the molecular etiology of this disease, we have developed murine models of this disease, in syngeneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rγnull mice engrafted with transformed human CD341 hematopoietic stem/progenitor cells. Both murine models mimic the human disease with splenohepatomegaly, hypercellular bone marrow, and myeloproliferative neoplasms that progresses to acute myeloid leukemia. Molecular genetic analyses of these model mice, as well as primary human disease, demonstrated that CNTRL-FGFR1, through abnormal activation of several signaling pathways related to development and differentiation of both myeloid and T-lymphoid cells, contribute to overt leukemogenesis. Clonal evolution analysis indicates that myeloid related neoplasms arise from common myeloid precursor cells that retain potential for T-lymphoid differentiation. These data indicate that simultaneously targeting these pathways is essential to successfully treating this almost invariably lethal disease.
UR - http://www.scopus.com/inward/record.url?scp=84886895019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886895019&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-03-489823
DO - 10.1182/blood-2013-03-489823
M3 - Article
C2 - 23777766
AN - SCOPUS:84886895019
SN - 0006-4971
VL - 122
SP - 1007
EP - 1016
JO - Blood
JF - Blood
IS - 6
ER -